The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A prospective phase II trial of pembrolizumab plus lenvatinib in advanced adrenal cortical carcinoma after failure of platinum- and mitotane-based chemotherapy (ACCOMPLISH).
 
Inkeun Park
No Relationships to Disclose
 
Minsuk Kwon
No Relationships to Disclose
 
Kwonoh Park
No Relationships to Disclose
 
Se Hoon Park
No Relationships to Disclose
 
Joo-Hwan Park
No Relationships to Disclose
 
Sang Joon Shin
No Relationships to Disclose
 
Hyun-Jeong Shim
No Relationships to Disclose
 
Tak Yun
No Relationships to Disclose
 
Jae-Lyun Lee
Stock and Other Ownership Interests - Amgen; BeiGene; Black Diamond Therapeutics; Innovent Biologics; Johnson & Johnson/Janssen; Karyopharm Therapeutics; Merck; Myovant Sciences; Zymeworks
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD
Consulting or Advisory Role - AstraZeneca; Merck; Oscotec; Sanofi
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); GI Innovation (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Oscotec (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Hyo Jin Lee
No Relationships to Disclose
 
Wonyoung Choi
No Relationships to Disclose